---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004687"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2022-03-25T23:59:59+00:00"
generated_at: "2026-06-26T17:26:49.957953+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Crinetics Chief Development Officer Ajay Madan resigns effective April 1, 2022

## Summary
- Ajay Madan, Ph.D., resigns as Chief Development Officer, effective April 1, 2022.
- Company expects to enter a six-month consulting agreement with Madan for transition support.
- Consulting retainer of approximately $37,346 per month.
- No replacement named; company will search for successor.

## SEC filing metadata
- accession: 0000950170-22-004687
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2022-03-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/0000950170-22-004687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/crnx-20220321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004687
- JSON: https://secwatch.observer/filing/0000950170-22-004687.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004687.txt

## Key facts
- Executive change
  Ajay Madan resigned as Chief Development Officer at Crinetics Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Development Officer
  source text: On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/0000950170-22-004687-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.